Table 4

Demographic and clinical characteristics of patients by blood eosinophil count recorded closest to initiation of the highest level of maintenance therapy

Variable<50
cells/µL (n=414)
50–349
cells/µL (n=9372)
≥350
cells/µL (n=2392)
P valueSMD
<50*
SMD
≥350†
Follow-up after index date, years
Median (IQR)6.1 (4.5–8.1)6.0 (4.4–8.2)5.9 (4.3–8.3)0.88050.10.4
Age (years) at index date
Mean (SD)66.3 (10.5)65.8 (9.9)66.0 (9.7)0.49964.61.9
Male sex, n (%)187 (45.2)4646 (49.6)1487 (62.2)<0.00018.825.6
BMI, n (%)
Underweight28 (6.8)263 (2.8)61 (2.6)<0.000125.90.7
Normal weight166 (40.1)2987 (31.9)735 (30.7)
Overweight125 (30.2)3365 (35.9)918 (38.4)
Obese95 (22.9)2757 (29.4)678 (28.3)
Baseline smoking status, closest within 5 years, n (%)n=379n=8787n=2257
Ex-smoker189 (49.9)4569 (52.0)1198 (53.1)0.43744.32.2
Smoking status up to 5 years of follow-up after index date, n (%)n=392n=8813n=2230
Sustained quitter132 (33.7)3190 (36.2)839 (37.6)0.24537.73.6
Intermittent quitter133 (33.9)3096 (35.1)784 (35.2)
Continuous smoker127 (32.4)2527 (28.7)607 (27.2)
Nasal polyps diagnosis ever, n (%)3 (0.7)73 (0.8)62 (2.6)<0.00010.614.1
Osteoporosis diagnosis ever, n (%)30 (7.2)429 (4.6)100 (4.2)0.022511.31.9
Charlson Comorbidity Index, n (%)
0–1163 (39.4)4108 (43.8)961 (40.2)0.01706.85.0
2–496 (23.2)1879 (20.0)529 (22.1)
5–951 (12.3)1260 (13.4)341 (14.3)
≥10104 (25.1)2125 (22.7)561 (23.5)
mMRC score, n (%)n=396n=9015n=2294
0–1254 (64.1)6165 (68.4)1586 (69.1)0.008014.43.0
≥2142 (35.9)2850 (31.6)708 (30.9)
GOLD groups (2017), n (%)n=396n=9015n=2294
A201 (50.8)5047 (56.0)1252 (54.6)0.00608.76.3
B114 (28.8)2296 (25.5)540 (23.5)
C53 (13.4)1118 (12.4)334 (14.6)
D28 (7.1)554 (6.1)168 (7.3)
FEV1 at index date
Mean (SD) absolute value (mL)1651.1 (493.9)1695.3 (491.4)1781.9 (499.2)<0.00019.017.5
Mean (SD) % predicted67.0 (10.1)66.4 (9.9)66.6 (9.8)0.22666.62.7
COPD exacerbations in year prior to highest therapy initiation, n (%)
0263 (63.5)5714 (61.0)1352 (56.5)0.00010.811.6
183 (20.0)2094 (22.3)545 (22.8)
236 (8.7)921 (9.8)269 (11.2)
316 (3.9)391 (4.2)135 (5.6)
≥416 (3.9)252 (2.7)91 (3.8)
Mean (SD)0.7 (1.4)0.7 (1.1)0.8 (1.2)0.00302.211.1
Cumulative daily dose of oral steroids in year prior to index date (mg /day), n (%)n=100n=2133n=641
No OCS5 (5.0)205 (9.6)64 (10.0)<0.000141.80.8
<2.572 (72.0)1719 (80.6)509 (79.4)
2.5-<58 (8.0)132 (6.2)43 (6.7)
5–7.58 (8.0)33 (1.5)13 (2.0)
≥7.57 (7.0)44 (2.1)12 (1.9)
GP consultations, all-cause, number in year prior to index date, n (%)
0–10 (0.0)49 (0.5)16 (0.7)0.018921.00.9
2–425 (6.0)679 (7.2)177 (7.4)
5–863 (15.2)1950 (20.8)486 (20.3)
9–13110 (26.6)2515 (26.8)657 (27.5)
14–1759 (14.3)1505 (16.1)379 (15.8)
18–2266 (15.9)1184 (12.6)306 (12.8)
23+91 (22.0)1490 (15.9)371 (15.5)
  • *As compared with the 50–349 cells/µL category.

  • †As compared with the 50–349 cells/µL category.

  • BMI, body mass index; GP, general practitioner; mMRC, modified Medical Research Council; P, p value for the Kruskal-Wallis equality-of-populations rank test, or the Pearson's chi-square test of independent categories, where appropriate; SMD, standardised mean difference.